Anti-TNF antibody therapy was developed to decrease inflammation in a variety of diseases such as inflammatory bowel disease (IBD), psoriasis, psoriatic arthritis, RA, ankylosing spondylitis, and juvenile idiopathic arthritis [63], emphasizing the role of TNF signaling in several illnesses [42]. This evidence concerns the gene TNF and ankylosing spondylitis.